Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells

Science  18 Sep 2009:
Vol. 325, Issue 5947, pp. 1555-1559
DOI: 10.1126/science.1174229

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Tumor progression is driven by genetic mutations, but little is known about the environmental conditions that select for these mutations. Studying the transcriptomes of paired colorectal cancer cell lines that differed only in the mutational status of their KRAS or BRAF genes, we found that GLUT1, encoding glucose transporter-1, was one of three genes consistently up-regulated in cells with KRAS or BRAF mutations. The mutant cells exhibited enhanced glucose uptake and glycolysis and survived in low-glucose conditions, phenotypes that all required GLUT1 expression. In contrast, when cells with wild-type KRAS alleles were subjected to a low-glucose environment, very few cells survived. Most surviving cells expressed high levels of GLUT1, and 4% of these survivors had acquired KRAS mutations not present in their parents. The glycolysis inhibitor 3-bromopyruvate preferentially suppressed the growth of cells with KRAS or BRAF mutations. Together, these data suggest that glucose deprivation can drive the acquisition of KRAS pathway mutations in human tumors.

  • * Present address: Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.

  • Present address: Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA.

  • Present address: Sanofi-Aventis, 13 Quai Jules Guesde, 94400 Vitry-sur-Seine, France.

View Full Text

Cited By...